Ramagrama Stupa the Sole Undisturbed Original Stupa Containing Relics of Lord Buddha to be Preserved and Developed
LUMBINI, NEPAL - Media OutReach - 23 October 2023 - The Promised Land is pleased…
3 years ago
FHA-HoReCa announces new initiatives and partnerships for 2024 edition, covering Technology Solutions and Talent recognition
Anticipate the debut of first-ever FSTEC Asia – catering to the surging demand for technology…
3 years ago
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed…
3 years ago
Bias in AI Computer Vision Systems Dramatically Reduced with Synthetic Data ‘Digital Humans’
Mindtech’s Digital DNA technology creates a diverse range of Digital Humans that allow for statistically…
3 years ago
APO’s Newest Member Turkiye Hosts 64th Workshop Meeting of Heads of National Productivity Organizations
ANKARA, Turkiye--(BUSINESS WIRE)--#APO--Turkiye, the Asian Productivity Organization’s (APO’s) newest member, generously hosted the 64th Workshop…
3 years ago
MindHub Academy 與廣州VV ARTç¶ç¶è—術創作åˆä½œ
MindHub Academy 與廣州VV ARTç¶ç¶è—術創作åˆä½œï¼ŒæŽ¨å‡ºå¤šæ¨£è—術課程，啟發創æ„æ–°æ½®æµ é¦™æ¸¯ - Media OutReach - 2023å¹´10月23æ—¥ - 在這個充滿活力的城市，一個令人振奮的消æ¯å³å°‡åœ¨è—術界掀起巨浪。MindHub Academy 和⌈廣州VV ARTç¶ç¶è—術創作…
3 years ago
Covation Holdings Continues Expansion in Asia Pacific With New Regional Corporate Headquarters
HONG KONG--(BUSINESS WIRE)--Covation Holdings Limited, the global manufacturer of multiple wheeled goods brands, today announced…
3 years ago
Berkshire Hathaway Specialty Insurance Names Sami Jaghbir as Underwriting Manager in Queensland
BRISBANE, Australia & BOSTON--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced that it has appointed…
3 years ago
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus…
3 years ago
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
Encouraging overall response rate of 46% and disease control rate of 98% with a median…
3 years ago